Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GIANT - A Multicenter, Prospective, Observational Study of Real-world Anti-TNFa Treatment Regimens of Hyrimoz™ (Adalimumab Biosimilar) or Zessly™ (Infliximab Biosimilar) in Patients With Crohn's Disease

NCT03890445 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT03890445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03890445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GIANT - A Multicenter, Prospective, Observational Study of Real-world Anti-TNFa Treatment Regimens of Hyrimoz™ (Adalimumab Biosimilar) or Zessly™ (Infliximab Biosimilar) in Patients With Crohn's Disease
Lead sponsor
Sandoz
Phase
Observational
Overall status
Completed
Start date
June 24, 2019
Completion date
May 8, 2020
Enrollment
63 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

crohn´s disease